BluntPenetrating Placebo rFVIIa Patients (%) n=20 n=8 n=9 n=4 P=0.03 P=0.068 Adapted from Rizoli S. Canadian Anesthesiologists’ Society Annual Meeting Need for Massive Transfusion (>20 units RBC): A Secondary Analysis

Comparison Odds ratio CI P value Entire patient cohort (unadjusted) All rFVIIa vs. no rFVIIa < Late rFVIIa vs. no rFVIIa < Early rFVIIa vs. no rFVIIa Entire patient cohort (adjusted) All rFVIIa vs. no rFVIIa Late rFVIIa vs. no rFVIIa Early rFVIIa vs. no rFVIIa Only rFVIIa-treated patients (adjusted) Early rFVIIa vs. no rFVIIa Adapted from Karkouti et al. Can an J Anaesth 2006;53(8): Risk of Adverse Events in 114 rFVIIa-treated Patients

Placebo (n=63) rFVIIa (n=49) Reduction P-value RBC (unit) <0.01 FFP (mL) 1, <0.01 Platelets (mL) Adapted from Rizoli S. Canadian Anesthesiologists Society Blood Transfusion Requirement in Coagulopathic Patients